TNGX Files Prospectus For $400M Common Stock
Tango Therapeutics files prospectus for up to $400M common stock offering
001 per share. We previously filed a prospectus supplement on November 21, 2025, relating to the offer and sale of shares of our common stock having an aggregate offering price of up to $100,000,000 from time to time through Leerink Partners, acting as our sales agent, or the prior prospectus supplement. As of the date of this prospectus supplement, we have sold an aggregate amount of approximately $64,389,566 of shares of our common stock under the prior prospectus supplement pursuant to the sales agreement.
We are terminating the offering pursuant to the prior prospectus supplement and we will not make any further offer or sale of shares of our common stock pursuant to the prior prospectus supplement. We are filing this prospectus supplement in accordance with the terms of the sales agreement, relating to the offer and sale of shares of our common stock having an aggregate offering price of up to $400,000,000 from time to time through Leerink Partners acting as our sales agent. 67 per share.